Shanghai Pharma in largest 2011 Hong Kong IPO so far
June 01, 2011 | BY
clpstaff &clp articlesThe H-share listing of Shanghai Pharmaceuticals Holdings (Shanghai Pharma) has raised US$2 billion on the Hong Kong Stock Exchange. At the time of writing,…
The H-share listing of Shanghai Pharmaceuticals Holdings (Shanghai Pharma) has raised US$2 billion on the Hong Kong Stock Exchange. At the time of writing, this stands as the largest initial public offering in Hong Kong this year.
The issuer is a vertically-integrated manufacturer and distributor of pharmaceuticals, and is China's second-largest drug distributor. It has numerous research, manufacturing, distribution and retail outlets.
The joint sponsors of the transaction were Goldman Sachs, China International Capital Corporation, Deutsche Bank and Credit Suisse.
A Freshfields Bruckhaus Deringer team advised Shanghai Pharma on Hong Kong and US law aspects. The underwriters were counselled on Hong Kong law by a Hong Kong-based Clifford Chance team led by Amy Lo and Jean Thio, while US counsel was Sullivan & Cromwell.
This premium content is reserved for
China Law & Practice Subscribers.
A Premium Subscription Provides:
- A database of over 3,000 essential documents including key PRC legislation translated into English
- A choice of newsletters to alert you to changes affecting your business including sector specific updates
- Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
Already a subscriber? Log In Now